Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LB-1908 by Legend Biotech for Gastric Cancer: Likelihood of Approval
LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
LB-1908 by Legend Biotech for Esophageal Cancer: Likelihood of Approval
LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
LB-1908 by Legend Biotech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...
Risk adjusted net present value: What is the current valuation of Legend Biotech's LB-1908?
LB-1908 is a gene-modified cell therapy commercialized by Legend Biotech, with a leading Phase I program in Adenocarcinoma Of The...
LB-1908 by Legend Biotech for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
LB-1908 is under clinical development by Legend Biotech and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According...